EN DE

Remegen Co Ltd (9995) Fair Value & Analysis

Healthcare · HK · Market cap HK$47.7B (≈ $6.1B) · ISIN CNE1000048G6

What is Remegen Co Ltd really worth?

RC Remegen Co Ltd 9995 · HK
PriceHK$80.00
Fair ValueHK$21.04
Upside−73.7%
Quality64/100

A solid business, but trading 280% above our fair value of HK$21.04.

Watch Remegen Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Highly profitable · 38.2% net margin

Risks

!Mixed Growth (revenue 5y +156.5 %/yr)
!Low debt · negative free cash flow
!Trails peers (5/13)
!Moderate moat 57/100
!Evidence only medium, so the estimate is less certain
!The models disagree: range HK$15.78 to HK$84.16
!Weak on dividend: 3 out of 100
Evidence: Medium Range HK$15.78 – HK$84.16

Fair value as of: Aug 28, 2026

From 17 valuation models · updated 8 days ago

Share price −3.1% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The model range is unusually wide (HK$15.78 to HK$84.16). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

HK$127.90 HK$10.62 Fair Value HK$21.04 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 28, 2026.

How to read this chart

60‑month range HK$10.62 – HK$127.90 · fair‑value band HK$15.78 – HK$84.16 · the HK$80.00 price screens above the HK$21.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 28, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Remegen Co Ltd (9995) currently trades at HK$80.00, while our model-based Fair Value estimate is HK$21.04, implying the stock looks roughly 280.2% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of HK$60.03 per share, and 0 of the 17 models we run sit above the HK$80.00 price. Bear case: the Economic Profit group reads lowest at HK$3.69, and 17 of the 17 models stay below the price. Evidence for this calculation is medium.

Over the trailing twelve months, Remegen Co Ltd generated revenue of HK$3.4B at a net margin of 38.2%. Revenue grew 24.8% year over year. It earns a return on equity of 45.3%. Net debt stands at HK$1.0B. Fundamentals as of Aug 28, 2026

Our scenario range runs from HK$15.78 (bear case) to HK$84.16 (bull case); at HK$80.00, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 37% below its 52-week high and 39% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −59% fair-value upside, at −74%, 9995 screens richer than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly HK$1.73 per share, which is 8.2 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (HK$2.05 to HK$61.27). Read the values as a conservative anchor, not as a price target.
Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
EPV best evidence HK$3.29 HK$3.69 HK$4.05 74
ROIC Compounder HK$3.29 HK$3.69 HK$4.05 70
Owner Earnings HK$24.48 HK$54.63 HK$117.91 68
All 17 models by family
DCF Models
Owner Earnings HK$24.48 HK$54.63 HK$117.91 68
Earnings-Based
Graham-Dodd HK$8.79 HK$61.27 HK$85.98 61
Lynch FV HK$31.65 HK$45.22 HK$58.79 59
PEG = 1.0 HK$31.65 HK$45.22 HK$58.79 55
EPV best evidence HK$3.29 HK$3.69 HK$4.05 74
Dividend Discount
Gordon GGM HK$1.17 HK$2.43 HK$3.85 64
DDM Multi-Stage HK$1.17 HK$2.05 HK$2.55 64
Multiples
P/E Multiple HK$21.32 HK$28.42 HK$35.53 63
P/S Multiple HK$15.49 HK$20.66 HK$25.82 58
P/B Multiple HK$16.47 HK$21.96 HK$27.46 55
EV/EBIT HK$4.48 HK$5.69 HK$6.90 66
EV/EBITDA HK$9.80 HK$12.79 HK$15.77 67
EV/Revenue HK$3.44 HK$4.55 HK$5.66 54
Asset-Based
NCAV (Graham) HK$3.29 HK$4.40 HK$6.57 54
Economic Profit
Residual Income HK$8.84 HK$12.41 HK$67.26 61
ROIC Compounder HK$3.29 HK$3.69 HK$4.05 70
Growth Earnings
Growth-Adj P/E HK$42.02 HK$60.03 HK$78.04 65

Widest divergence: Growth Earnings (HK$60.03) versus Dividend Discount (HK$2.05). Highest evidence: EPV (74).

Notify me when 9995 reaches fair value

Put 9995 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 53.7 as of Jul 3, 2026
P/S ratio 11.8 P/E × margin
EPS (TTM) HK$2.55 price ÷ EPS = P/E 53.7
Dividend yield 0.1% payout 4.6%
Net margin 21.9% FY2025
Return on equity 45.3% TTM
More key figures
Profitability
Return on assets (EBIT) −12.4% avg 5y
Operating margin −3.4% TTM
Growth
Revenue (TTM) HK$3.4B TTM
Revenue growth (YoY) +24.8% 3y avg +61.6%
Balance sheet & cash flow
Free cash flow −HK$140M FY2025
Net debt HK$1.0B FY2025

Figures from reported company fundamentals · as of Aug 28, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 59 · Market factors (momentum, volatility) 41

Profitability 64
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 63
Balance sheet, leverage, solvency risk
Investment 82
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 45
Price trend over the last 3–12 months (market factor)
52W Momentum 26
Distance to the 52-week high (market factor)
Net Issuance 65
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.

Full company description

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Remegen Co Ltd reported revenue of 3.2B CNY in FY2025 versus 1.4B CNY in FY2021, a compound +22.8%/yr. Reported net income was 710M CNY in FY2025, compounding +26.6%/yr from FY2021.

Growth Quality 59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
HK$3.2B
Latest YoY
+88.8%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+61.6%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+156.5%
Avg. revenue growth/yr (7Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+124.4%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
+18.0% (17.9 + 0.1)
Revenue +22.8%/yr
FY21 1.4B CNY
FY22 768M CNY
FY23 1.1B CNY
FY24 1.7B CNY
FY25 3.2B CNY
Net income +26.6%/yr
FY21 276M CNY
FY22 −998M CNY
FY23 −1.5B CNY
FY24 −1.5B CNY
FY25 710M CNY

9995 screens 280% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Remegen Co Ltd · Fair Value
HK$21.04 −280%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Remegen Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/9995

Peer Group

Biotechnology · 622 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 64 · Top 25%
Fair Value upside −74% · Bottom 25%
Return on equity (TTM) 45% · Top 25%
Return on assets 3% · Top 25%
Net margin (TTM) 38% · Top 25%
Operating margin (TTM) −3% · Below median
Revenue growth 25% · Above median
Dividend yield (TTM) 0.1% · Bottom 25%
Debt / equity 0.20× · Higher than median

Valuation Multiples vs Biotechnology median · lower = cheaper

P/E (TTM) 53.7× · Pricier than 75% of peers
P/B 13.21× · Pricier than 75% of peers
P/S (TTM) 14.10× · Pricier than 75% of peers
EV/EBITDA 78.9× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE100 · sector 0
PAST100 · sector 0
HEALTH90 · sector 98
DIVIDEND3 · sector 26

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 28, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $547.55 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $807.71 $594.40 −26%
argenx SE ARGX €877.60 €292.84 −67%
Samsung Biologics Co 207940 1,518,000 KRW 1,055,793 KRW −30%
CSL Limited CSL A$174.50 A$141.68 −19%
Alnylam Pharmaceuticals, Inc ALNY $228.61 $51.70 −77%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BeOne Medicines AG ONC $362.51 $111.35 −69%
BioNTech SE BNTX $111.40 $45.66 −59%

Compare Remegen Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Remegen Co Ltd (9995) overvalued or undervalued?
As of Aug 28, 2026, our model estimates a fair value of HK$21.04 versus a price of HK$80.00, about −74% upside (overvalued).
What is the fair value of 9995?
Our model-based fair value for Remegen Co Ltd is HK$21.04 (as of Aug 28, 2026), built from audited fundamentals. The current price: HK$80.00.
What is the quality score of 9995?
Remegen Co Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Remegen Co Ltd (9995)?
Remegen Co Ltd reported trailing-twelve-month revenue of about HK$3.4B (latest available figure, as of Aug 28, 2026).
What is the net profit margin of 9995?
The net profit margin of Remegen Co Ltd is about 38.2%, meaning it keeps roughly 38.2% of revenue as net income. Based on the latest reported figures.
Does Remegen Co Ltd pay a dividend?
Remegen Co Ltd currently shows a dividend yield of about 0.15% relative to its recent price (as of Aug 28, 2026).
Free · no account needed

Watch Remegen Co Ltd in the live analysis

One click puts Remegen Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.